Valuation Metrics Reflect Elevated Pricing
As of the latest assessment, Yatharth Hospital’s P/E ratio stands at 39.21, a level that categorises the stock as expensive compared to its historical valuation band. This is a significant increase from prior valuations where the stock was considered fairly priced. The price-to-book value ratio has also risen to 3.89, reinforcing the premium investors are currently paying for the company’s equity relative to its net asset value.
Other valuation multiples further underline this trend. The enterprise value to EBITDA (EV/EBITDA) ratio is at 24.25, while the enterprise value to EBIT (EV/EBIT) ratio is 33.29. These multiples are elevated but remain within a range consistent with the hospital sector’s growth expectations, albeit on the higher side compared to some peers.
Comparative Analysis with Industry Peers
When benchmarked against key competitors in the hospital industry, Yatharth Hospital’s valuation appears more moderate but still expensive. For instance, Aster DM Healthcare and Krishna Institute of Medical Sciences trade at P/E ratios of 92.65 and 94.29 respectively, both categorised as expensive. Dr Lal Pathlabs, another prominent player, is rated very expensive with a P/E of 42.07 and an EV/EBITDA of 28.78.
Yatharth’s valuation multiples are notably lower than these high-profile peers, suggesting some relative value within the expensive category. However, the company’s PEG ratio of 1.37 indicates that the price premium is not fully justified by earnings growth prospects, which may concern value-focused investors.
Operational Efficiency and Returns
From an operational standpoint, Yatharth Hospital’s return on capital employed (ROCE) is 12.32%, while return on equity (ROE) is 9.03%. These figures indicate moderate efficiency in generating returns from capital and equity, but they lag behind some industry leaders who typically report ROCE and ROE in the mid to high teens. This gap may partly explain the cautious stance reflected in the company’s Mojo Grade downgrade from Hold to Sell on 6 February 2026.
The downgrade aligns with the valuation shift, signalling that despite the company’s growth potential, the current price levels may not offer sufficient margin of safety for investors.
Market Performance and Price Movement
Yatharth Hospital’s stock price has shown resilience in recent periods, with a 1-year return of 85.47%, significantly outperforming the Sensex’s 5.52% gain over the same timeframe. The stock’s 52-week high is ₹843.00, while the current price hovers around ₹681.05, reflecting some retracement from peak levels but still elevated compared to the 52-week low of ₹360.40.
Shorter-term returns have been modestly positive, with a 1-month gain of 0.77% and a 1-week gain of 0.29%, both outperforming the Sensex’s negative returns in these periods. Year-to-date, the stock is slightly down by 0.07%, yet this is still better than the Sensex’s 8.23% decline, indicating relative strength amid broader market weakness.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Implications of Valuation Grade Change
The transition of Yatharth Hospital’s valuation grade from fair to expensive has important implications for investors. The elevated P/E and P/BV ratios suggest that the market is pricing in strong future growth and operational improvements. However, the company’s current return metrics and PEG ratio indicate that earnings growth may not fully justify the premium valuation.
Investors should weigh the risk of a valuation correction if growth expectations are not met or if sector headwinds intensify. The hospital sector faces challenges such as regulatory changes, rising costs, and competitive pressures, which could impact profitability and investor sentiment.
Sector and Market Context
The hospital sector remains an attractive long-term growth theme driven by rising healthcare demand, increasing insurance penetration, and technological advancements. However, valuations across the sector are generally elevated, with many companies trading at premium multiples reflecting growth optimism.
Yatharth Hospital’s current valuation places it in the expensive category but still below some of the highest-valued peers. This relative positioning may appeal to investors seeking exposure to the sector with a somewhat more moderate valuation risk.
Summary and Outlook
In summary, Yatharth Hospital & Trauma Care Services Ltd has seen a clear shift in its valuation parameters, moving into expensive territory as reflected by a P/E of 39.21 and a P/BV of 3.89. While the stock has outperformed the broader market over the past year, the recent downgrade to a Sell rating and the valuation premium warrant caution.
Investors should closely monitor the company’s operational performance, earnings growth trajectory, and sector developments to assess whether the current valuation remains justified. Those with a lower risk tolerance may consider waiting for a more attractive entry point or exploring alternative hospital stocks with better valuation metrics and growth prospects.
Yatharth Hospital & Trauma Care Services Ltd or something better? Our SwitchER feature analyzes this small-cap Hospital stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Mojo Score and Rating Context
Yatharth Hospital currently holds a Mojo Score of 42.0, which corresponds to a Sell grade, a downgrade from its previous Hold rating on 6 February 2026. This reflects a more cautious stance by analysts, factoring in the stretched valuation and moderate operational returns. The company’s market cap grade is 3, indicating a small-cap classification, which typically entails higher volatility and risk.
The downgrade and valuation shift suggest that investors should exercise prudence and consider the risk-reward balance carefully before initiating or adding to positions in this stock.
Price Action and Trading Range
On 11 March 2026, Yatharth Hospital’s stock price closed at ₹681.05, up 2.51% from the previous close of ₹664.40. The intraday trading range was ₹668.30 to ₹687.15, indicating some buying interest near current levels. The stock remains below its 52-week high of ₹843.00 but well above the 52-week low of ₹360.40, reflecting a strong recovery and upward momentum over the past year.
Investors should watch for potential resistance near the upper end of the trading range and monitor volume trends for confirmation of sustained buying interest.
Conclusion
Yatharth Hospital & Trauma Care Services Ltd’s valuation has shifted from fair to expensive, driven by rising P/E and P/BV ratios amid moderate operational returns. While the stock has delivered strong price appreciation over the past year, the recent downgrade to Sell and elevated valuation multiples suggest caution. Investors should carefully evaluate growth prospects, sector dynamics, and relative valuation before committing capital.
Given the current market environment and valuation landscape, a selective approach is advisable, with consideration of alternative hospital stocks offering better value or stronger fundamentals.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
